Electrophysiological Study of Campbell Line Rats Before and After the Administration of Drugs
DOI:
https://doi.org/10.61841/tk7fa974Keywords:
Retinitis Pigmentosa, ERG, Retinalaminum, OMK1Abstract
The study includes the evaluation of the total bioelectric activity of a, b, and c waves of the electroretinogram (ERG) and mean values of the amplitude of b-waves in the retina of Campbell rats of different ages before and after the administration of the drugs (Retinalaminum and Retinalaminum + Omk1). The study results showed that the administration of Retimalaminum and Retinalaminum + Omk1 to neonate rats led to a significant improvement in the total bioelectric activity of the waves a, b, and c of ERG. A significant increase in this parameter value was also observed in neonate rats after the combined administration of Retinalaminum + Omk1 in comparison with the group of rats that received only Retinalaminum. In adult rats, the administration of the abovementioned parameters improved the bioelectric activity of the waves a,b,c of ERG, but there were no significant differences between the administration of Retinalaminum and Retinalaminum in combination with Omk1 revealed. There were no significant data on the improvement of bioelectrical activity in senior rats after the administration of the drugs. The study of the mean values of b-wave in rats of different ages revealed the same consistency as it was observed in the total bioelectrical activity according to ERG.
Downloads
References
[1] Galbinur T.P., Novikova E.A. The evaluation of para-aminobenzoic acid on the morphological condition of the retina in rd10 mice—model of pigmented retinitis. Ophthalmology. Moscow, 2012, v. 9, №3, p.57-60.
[2] Zhukova S.I. Pathogenetic grounds of the classification features of the development of pigmented retinitis. Dissertation, Irkutsk, 2005, p. 132.
[3] Zolnikova I.V. Multifocal electroretinography in the diagnostics of inherited and age-related degeneration of the retina. Dissertation, Moscow, 2012. p. 329.
[4] Ryabinina M.V. The development of a new approach to the treatment of patients with different stages of pigmented abiotrophy of the retina with desoxynatum. Dissertation, 1999, p. 16.
[5] Takhchidi Kh.P., Gavrilova N.A., Komova O.Y. et al. The influence of stem/progenitor cells on the functional condition and degree of the expression of the degenerative changes in Campbell line rats. Ophthalmosurgery, 2010, №3, p. 33-38.
[6] Trofimova S.V. Age-related peculiarities of the regulatory effect of the peptides in patients with pigmented degeneration of the retina (experimental-clinical study). Dissertation. SPb, 2003, p. 378.
[7] Khavinson V.Kh., Pronyaeva V.E., Linkova N.S., Trofimova S.V., Umnov R.S. Molecular aspects of peptide regulation of the functions of the retina in patients with pigmented retinitis. Human physiology, 2014, v. 40, №1, p. 111-116.
[8] Khavinson V.Kh., Seryi S.V., Kozhemyakin A.L., Valeev R.I. Remedy for the restoration of the function of the retina. Pat. 2073518 Russian Federation, МПК6 A61K 35/44, A 61F 9/00. №93030389/14; Applied on 17.06. 1993; Published on 20.02.1997.
[9] Khasanova N.Kh., Belyaeva A.V. The results of the administration of Retinalaminum in patients with retinal diseases. KOFT, Neuroprotection in ophthalmology, 2008, v. 9, №3, p. 77-82.
[10] Nagy D., Schonfisch B., Zrenner et al. Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography. Invest. Ophthalmol. Vis. Sci., 2008, 49(10), p.4664-4671
[11] Dolan F., Parks S., Hammer H., Keating D. The wide-field multifocal electroretinogram reveals retinal dysfunction in early retinitis pigmentosa. British Journal of Ophthalmology, 2002, 86 (4), p.480-481
[12] Galbinur T.P., Oboensky A., Berenshtein E., Vinokur V., Chowers I. et al. Effect of para-aminobenzoic acid on the course of retinal degeneration in the rd10 mouse. Journal of Ocular Pharmacology Therapeutics, 2009, v.25 (6), pp.475-482.
[13] Hafezi F., Grimm C., Simmen B., Wenzel A., Reme C. Molecular ophthalmology: an update on animal models for retinal degenerations and dystrophies. British Journal of Ophthalmology, 2000, 84 (8), p.922-927
[14] Hara A., Niwa M., Kunisada T. et al. Embryonic stem cells are capable of generating a neuronal network in the adult mouse retina. Brain Res, 2004, 999. (2). p. 216-221
[15] He L., Silva R.A., Moshfeghi D.M. et al. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina, 2016, 36(3), p.492-498
[16] Kharouzov A.K., Shelepin L.E., Pozdeev N.V., Etingof R.N. Changes in the electroretinogram of Campbell rats with the development of hereditary retinal degeneration. Journal of Physiology named after I.M. Sechenova. Russian Academy of Sciences, 1996, 82(8-9), p.73-79
[17] Kharauzov A.K., Etingof R.N. Change on Schrödinger rats line Campbell in the development of hereditary retinal degeneration. Physiology - 2014 - № 9. - p. 65-71
[18] Melissa M., Jingsheng T., Chio-Chao Ch. Gene therapy for ocular diseases. British Journal of Ophthalmology, 2011, 95 (5), p.604-612
[19] Paskowitz D., La Vail M., Duncan J. Light and inherited retinal degeneration. British Journal of Ophthalmology, 2006, 90 (8), p.1060-1066
[20] Reichel M., Bainbridge J., Baker D., Thrasher A. et al. An immune response after intraocular administration of an adenoviral vector containing a β-galactosidase reporter gene slows retinal degeneration in the rd mouse. British Journal of Ophthalmology, 2001, 85 (3), p.341-344
[21] Sagdullayev B.T., Aramant R.B., Seiler M.J. et al. Retinal transplantation–induced recovery of retinotectal visual function in a rodent model of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci., 2003, 44(4), p.1686-1695
[22] Seeliger M., Kretschmann U., Apfelstedt-Sylla E., Ruther K., Zrenner E. Multifocal electroretinography in retinitis pigmentosa. American Journal of Ophthalmology, 1998, Vol. 125, Issue 2, p.214-226
[23] Victor Chong N., Bird A. Management of inherited outer retinal dystrophies: present and future. British Journal of Ophthalmology, 1999, 83 (1), p.120-122
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
